Table 5 |
||||||
|
Comparison of the three treated groups with GERD |
||||||
|
Melatonin |
Omeprazole |
Melatonin and Omeprazole |
P value |
|||
|
|
||||||
|
P1 |
P2 |
P3 |
||||
|
|
||||||
|
A)Symptoms: |
||||||
|
Heart burn: |
||||||
|
control |
0 |
0 |
0 |
|||
|
pretreatment: |
||||||
|
yes |
7 |
7 |
8 |
|||
|
duration (months) |
1.3 ± 0.4 |
1.2 ± 0.3 |
1.4 ± 0.4 |
|||
|
4 weeks |
||||||
|
8 weeks |
3(57.1%) |
2(71.4%) |
1(87.5%) |
|||
|
0(100%) |
0(100%) |
0(100%) |
||||
|
|
||||||
|
Epigastric pain: |
||||||
|
-control |
0 |
0 |
0 |
|||
|
pretreatment: |
||||||
|
yes |
6 |
6 |
6 |
|||
|
duration (months) |
1.4 ± 0.5 |
1.3 ± 0.4 |
1.3 ± 0.4 |
|||
|
4 weeks |
3(50%) |
2(66.7%) |
1(83.3%) |
|||
|
8 weeks |
1(83%) |
0(100%) |
0(100%) |
|||
|
|
||||||
|
B) LES Study: |
P1 |
P2 |
P3 |
|||
|
1-LES pressure(mmHg) |
||||||
|
control |
22.8 ± 1.3 |
22.8 ± 1.3 |
22.8 ± 1.3 |
0.9 |
0.9 |
0.9 |
|
pretreatment: |
10 ± 1.58 |
10.5 ± 2.86 |
10.3 ± 1.68 |
0.65 |
0.7 |
0.86 |
|
4 weeks |
14.5 ± 1.58 |
10.4 ± 4.05 |
14.5 ± 1.26 |
0.006 |
0.468 |
0.002 |
|
8 weeks |
20.2 ± 1.56 |
10.5 ± 2.85 |
20.5 ± 1.22 |
0.000 |
0.68 |
0.000 |
|
|
||||||
|
2-Residual pressure (mmHg) |
P1 |
P2 |
P3 |
|||
|
- control |
0.4 ± 0.01 |
0.4 ± 0.01 |
0.4 ± 0.01 |
1.0 |
1.0 |
1.0 |
|
pretreatment: |
0.012 ± 0.52 |
0.1 ± 0.064 |
0.012 ± 0.44 |
0.578 |
1.00 |
0.556 |
|
4 weeks |
0.2 ± 0.016 |
0.2 ± 0.15 |
0.21 ± 0.016 |
1.00 |
0.198 |
0.198 |
|
8 weeks |
0.32 ± 0.013 |
0.1 ± 0.07 |
0.33 ± 0.016 |
0.000 |
0.08 |
0.000 |
|
|
||||||
|
3-Relaxation duration (seconds) |
P1 |
P2 |
P3 |
|||
|
control |
5.0 ± 0.1 |
5.0 ± 0.1 |
5.0 ± 0.1 |
1.0 |
1.0 |
1.0 |
|
pretreatment:: |
6.8 ± 0.12 |
6.5 ± 2.74 |
6.8 ± 0.16 |
0.747 |
1.000 |
0.747 |
|
4 weeks |
5.9 ± 0.16 |
6.3 ± 2.7 |
5.8 ± 0.13 |
0.662 |
0.153 |
0.585 |
|
8 weeks |
5.3 ± 0.12 |
6.3 ± 2.65 |
5.2 ± 0.12 |
0.747 |
0.102 |
0.059 |
|
|
||||||
|
4-Relaxation % |
P1 |
P2 |
P3 |
|||
|
control |
100 ± 0.00 |
100 ± 0.00 |
100 ± 0.00 |
1.0 |
1.0 |
1.0 |
|
pretreatment: |
86 ± 0.87 |
87.2 ± 0.17 |
85 ± 1.58 |
0.12 |
0.116 |
0.14 |
|
4 weeks |
90 ± 0.86 |
87.3 ± 0.25 |
90 ± 1.23 |
0.1 |
1.000 |
0.1 |
|
8 weeks |
100 ± 0.00 |
87.1 ± 0.1 |
100 ± 0.00 |
0.01 |
1.00 |
0.01 |
|
|
||||||
|
C) PH (at 5 cm above the LES): |
P1 |
P2 |
P3 |
|||
|
control: |
7.8 ± 0.4 |
7.8 ± 0.4 |
7.8 ± 0.4 |
1.0 |
1.0 |
1.0 |
|
pretreatment: |
2.3 ± 0.36 |
2.1 ± 0.38 |
1.98 ± 0.37 |
0.1 |
0.1 |
0.1 |
|
4 weeks |
5.2 ± 0.5 |
5.9 ± 0.48 |
6.1 ± 0.55 |
0.008 |
0.002 |
0.09 |
|
8 weeks |
6.7 ± 0.65 |
7.2 ± 0.32 |
7.5 ± 0.31 |
0.01 |
0.008 |
0.1 |
|
|
||||||
|
D) BAO(mmol/h) |
P1 |
P2 |
P3 |
|||
|
- control: |
2.6 ± 0.6 |
2.6 ± 0.6 |
2.6 ± 0.6 |
1.0 |
1.0 |
1.0 |
|
pretreatment: |
24.7 ± 0.5 |
25.1 ± 0.6 |
24.9 ± 0.7 |
0.1 |
0.1 |
0.1 |
|
4 weeks |
20.1 ± 0.4 |
17.2 ± 0.7 |
15.8 ± 0.9 |
0.008 |
0.002 |
0.09 |
|
- 8 weeks |
16.6 ± 0.6 |
11.5 ± 0.6 |
10.2 ± 0.9 |
0.01 |
0.008 |
0.1 |
|
|
||||||
|
E) Serum Gastrin(pg/ml) |
P1 |
P2 |
P3 |
|||
|
control: |
41.8 ± 7.1 |
41.8 ± 7.1 |
41.8 ± 7.1 |
1.0 |
1.0 |
1.0 |
|
pretreatment: |
22.1 ± 4.2 |
21.5 ± 4.6 |
21.9 ± 4.7 |
0.1 |
0.1 |
0.1 |
|
4 weeks |
27.2 ± 2.3 |
32.1 ± 2.1 |
33.6 ± 2.7 |
0.008 |
0.002 |
0.09 |
|
- 8 weeks |
32.3 ± 2.1 |
35.9 ± 1.8 |
36.8 ± 2.1 |
0.01 |
0.008 |
0.1 |
|
|
||||||
|
D) Melatonin level at day time (pg/ml): |
P1 |
P2 |
P3 |
|||
|
control |
36.1 ± 2.3 |
36.1 ± 2.3 |
36.1 ± 2.3 |
1.0 |
1.0 |
1.0 |
|
pretreatment: |
18.2 ± 5.54 |
18.5 ± 3.75 |
18.3 ± 3.8 |
0.1 |
0.665 |
0.472 |
|
4 weeks |
28.26 ± 2.26 |
19.2 ± 3.47 |
28.83 ± 1.82 |
0.000 |
0.55 |
0.000 |
|
8 weeks |
34.5 ± .35 |
17.9 ± 3.72 |
34.5 ± 2.35 |
0.000 |
1.00 |
0.000 |
|
|
||||||
|
P1: group III versus group II P2: group IV versus group II P3: group IV versus group III |
||||||
|
Kandil et al. BMC Gastroenterology 2010 10:7 doi:10.1186/1471-230X-10-7 |
||||||
